

05 December 2005



**National Institute for
Health and Clinical Excellence**

MidCity Place
71 High Holborn
London
WC1V 6NA

Tel: +44 (0)20 7067 5800

Fax: +44 (0)20 7067 5801

nice@nice.org.uk

www.nice.org.uk

Dear Sir or Madam

Health Technology Appraisal

**Review of NICE Technology Appraisal Guidance No.55, on the use of paclitaxel
(1st line only) in the treatment of ovarian cancer**

As you may be aware the planned date for consideration of the review of the above guidance is December 2005. This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal. We were expecting that the results of the ICON5 trial would be available to inform the decision to review by this time.

We have been informed by the MRC that the survival results from ICON5 will not now be ready until the autumn of 2006. We are therefore letting you know that we will be monitoring the availability of these results from early autumn next year, and will contact all consultees with our proposals for the review of the use of paclitaxel 1st line, in the light of these results.

Information on this approach will be published on the Institute's website (www.nice.org.uk) on 12th December 2005 and is confidential in the interim.

In the meantime if you have any queries please contact Bijal Chandarana by phone on 020 7067 5919.

Yours faithfully

Dr Carole Longson
Director, Centre for Health Technology Evaluation

National Institute for Health & Clinical Excellence
Proposals for review of NICE Technology Appraisal Guidance No.55, the use of paclitaxel
(1st line only) in the treatment of ovarian cancer
Date: December 2005

If you have any queries regarding this correspondence please contact Bijal Chandarana by email at bijal.chandarana@nice.org.uk or by phone at 020 7067 5919.